Compare LCUT & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCUT | IKT |
|---|---|---|
| Founded | 1945 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.8M | 215.2M |
| IPO Year | 1996 | 2020 |
| Metric | LCUT | IKT |
|---|---|---|
| Price | $8.88 | $1.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $5.00 | $5.00 |
| AVG Volume (30 Days) | 180.7K | ★ 660.0K |
| Earning Date | 05-07-2026 | 03-26-2026 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | N/A | ★ 57.76 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $647,933,000.00 | N/A |
| Revenue This Year | $3.74 | N/A |
| Revenue Next Year | $1.20 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.90 | $1.33 |
| 52 Week High | $9.80 | $2.26 |
| Indicator | LCUT | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 58.69 | 39.09 |
| Support Level | $3.44 | $1.51 |
| Resistance Level | $9.80 | $1.74 |
| Average True Range (ATR) | 0.81 | 0.09 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 65.23 | 38.46 |
Lifetime Brands Inc is a U.S.-based company that designs, sources, and sells branded kitchenware, tableware, and other home solution products used in the home. The company's product portfolio comprises kitchen tools, cutlery, thermometers, cutting boards, spice racks, dinnerware, stemware, flatware, bath scales, thermal beverage ware, food storage, neoprene travel products, etc. These products are marketed under owned or licensed brands like Farberware, KitchenAid, Mikasa, Misto, Taylor, Sabatier, and Pfaltzgraff, among others. The company mainly sells its products directly to retailers and distributors, and a limited selection directly to consumers through its own websites. It has two reportable operating segments: U.S., which derives maximum revenue, and International.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.